Research and Markets has announced the addition of the "Global Multiple Sclerosis Drugs Market 2014-2018" report to their offering.
Multiple sclerosis is a chronic, inflammatory medical condition that results in demyelination, axonal transection, and neurodegeneration. The myelin sheath is damaged because of an abnormal response by the immune system, which targets neurons within the central nervous system (CNS). It is a potentially debilitating disease in which the damage of the myelin sheath causes disruption in the communication and coordination functions of the body.
The symptoms of multiple sclerosis differ widely, subject to the extent of damage and the number of neurons affected. Some of the symptoms observed in a patient with multiple sclerosis are fatigue, numbness, spasticity, bladder dysfunction, cognitive changes, emotional changes, and depression. An individual with the severe course of the disease can experience speech problems and movement problems.
Multiple sclerosis can be broadly classified into four types: relapsing-remitting multiple sclerosis, secondary-progressive multiple sclerosis, primary-progressive multiple sclerosis, and progressive-relapsing multiple sclerosis. On the basis of the route of drug administration, the Global Multiple Sclerosis Drugs market can be segmented into two: Oral Drugs, and Parenteral Drugs.
The analysts forecast the Global Multiple Sclerosis Drugs market to grow at a CAGR of 5.56 percent over the period 2013-2018.
This report covers the present scenario and the growth prospects of the Global Multiple Sclerosis Drugs market for the period 2014-2018. To calculate the market size, the report considers the revenue generated from the sales of various drugs used for the treatment of multiple sclerosis.
The report, the Global Multiple Sclerosis Drugs Market 2014-2018, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Multiple Sclerosis Drugs market landscape and its growth prospects in the coming years. The report includes a discussion of the key vendors operating in this market.
Key Topics Covered:
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
04. Product Profiles
05. Market Research Methodology
07. Rate of Incidence and Prevalence
08. Market Segmentation by Molecule Type
09. Market Segmentation by Route of Administration
10. Geographical Segmentation
11. Buying Criteria
12. Market Growth Drivers
13. Drivers and their Impact
14. Market Challenges
15. Impact of Drivers and Challenges
16. Market Trends
17. Trends and their Impact
18. Vendor Landscape
19. Key Vendor Analysis
20. Other Reports in this Series
- EMEA Key Vendors
- Biogen Idec
- Merck Serono
- Teva Pharmaceutical
- AB Science
- Active Biotech
- Mitsubishi Tanabe